The Tohoku Journal of Experimental Medicine
Online ISSN : 1349-3329
Print ISSN : 0040-8727
ISSN-L : 0040-8727
Regular Contributions
Improved Survival of Children with Advanced Tumors by Myeloablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation in Complete Remission
Atsushi Sato, Masue Imaizumi, Takako Saisho, Toshiaki Saito, Miyako Yoshinari, Yan Cui, Hoshiro Suzuki, Yoshitsugu Koizumi, Tsuneo Ito, Yoshihiro Takai, Yutaka Hayashi, Makoto Tamura, Kazuie Iinuma
Author information
Keywords: PBSCT, children, neuroblastoma, rhabdomyosarcoma, complete remission
JOURNAL FREE ACCESS

1998 Volume 186 Issue 4 Pages 255-265

Details
Download PDF (708K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

Five children with neuroblastoma (NB) stage IV and five children with rhabdomyosarcoma (RMS) stage III were treated with myeloablative chemotherapy and autologous peripheral blood stem cell transplantation (MCT/PBSCT) in the state of complete remission (CR) achieved by conventional therapy. PBSCs were collected in CR status using a cell separator with blood access through a double-lumen central venous catheter. PBSCs with 1.9±0.8×105 of CFU-GM per patient weights (kg) were infused following MCT after a period of conventional therapy for 11.1±2.1 or 9.7±0.9 months in NB or RMS patients, respectively. Regimen-related toxicity of MCT was tolerable and peripheral white blood cell count recovered beyond 1.0×103/μl 10-12 days after infusion of PBSCs in all patients. All of RMS patients and three of five NB patients survived for an average of 31.6 months (ranged 10.8-58.1). The survival rate of these patients was improved as compared with our historical controls, and presumably, with that of conventional chemotherapy previously reported. Despite a limited number of patients, it appears that MCT/PBSCT may be effective in improving survival by preventing relapse which may occur thereafter if treated with conventional therapy alone. Furthermore, MCT/PBSCT reduced the duration of treatment, as compared with that of conventional chemotherapy. Therefore, this study may suggest the feasibility and promise of the therapy including MCT/PBSCT for children with advanced stages of NB and RMS.

Content from these authors
© 1998 Tohoku University Medical Press
Previous article Next article
Favorites & Alerts

Recently viewed articles
  • About this Journal
    The Tohoku Journal of Experimental Medicine (TJEM) was founded in 1920 by professors of Tohoku Imperial University, Medical School. The TJEM has been published continuously, except for the year of 1946 just after the World War II. The TJEM is open to original articles in all branches of medical sciences. The TJEM also covers the fields of disaster-prevention science, including earthquake archeology.

  • Submitted manuscripts will be screened for plagiarism with Similarity Check (https://www.crossref.org/services/similarity-check/).
Announcements from publisher
  • Subscriptions
    Inland subscriptions should be sent to Tohoku University Medical Press, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, JAPAN.

    Subscriptions from abroad should be addressed to MARUZEN CO., LTD., EXPORT DEPARTMENT, Postal address: P.O.Box 75, Shinagawa, Tokyo 140-8799, JAPAN. 
    e-mail: export@maruzen.co.jp
Share this page
feedback
 Top